Microbot Medical Inc. (MBOT) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Microbot Medical Inc., a medical device company specializing in robotic endoluminal surgery devices. The reporting period covers the three and nine months ended September 30, 2025. The Company is a smaller reporting company and a non-accelerated filer. As of November 12, 2025, there were 67,158,044 shares of Common Stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(3,577) | $(9,678) | N/A |
| Operating Loss | $(3,861) | $(10,605) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $6,704 |
| Marketable Securities | N/A | N/A | $73,454 |
| Total Assets | N/A | N/A | $81,760 |
| Total Liabilities | N/A | N/A | $3,536 |
| Shareholders' Equity | N/A | N/A | $78,224 |
| Net Cash Used in Operating Activities | N/A | $(9,288) | N/A |
| Net Cash Provided by Financing Activities | N/A | $83,734 | N/A |
Note: The Company has not generated any revenue to date. Expenses are primarily driven by Research and Development (R&D) and Sales, General, and Administrative (SG&A) costs.
Material Changes vs. Prior Period
- Liquidity Position: Total assets increased significantly from $6.0 million (Dec 31, 2024) to $81.8 million (Sept 30, 2025), driven by a surge in marketable securities from $2.4 million to $73.5 million following capital raises.
- Capital Structure: Shares outstanding increased from 19.4 million (Dec 31, 2024) to 65.8 million (Sept 30, 2025) due to registered direct offerings, warrant exercises, and an inducement transaction.
- Operating Expenses:
- R&D expenses decreased for the three months ended Sept 30, 2025 ($1.17M) compared to the prior year ($2.06M), largely due to the recognition of a new Israeli Innovation Authority (IIA) grant and a reversal of provisions, offset by increased outsourcing and payroll costs.
- SG&A expenses increased significantly for the three months ended Sept 30, 2025 ($2.69M) compared to the prior year ($1.24M), driven by new hires for commercialization, salary increases, and bonuses.
- Financing Income: Net financing income increased to $284k for the quarter (from $85k in 2024) due to interest earned on the expanded portfolio of marketable securities.
Guidance, Outlook, and Risks
- Product Milestones: The Company received FDA 510(k) clearance for the LIBERTY® Endovascular Robotic Surgical System on September 8, 2025. It also obtained ISO 13485:2016 certification in August 2024, anticipating CE Mark approval in the second half of 2026.
- Liquidity Outlook: Management believes available funds (approx. $80.2M in cash and marketable securities) are sufficient to fund operations for more than twelve months from the issuance date.
- Capital Raising: The Company raised approximately $83.7 million in net cash from financing activities in the first nine months of 2025. This included registered direct offerings, ATM sales, and a significant "Inducement Transaction" in September 2025 where investors exercised existing options in exchange for new options.
- Risks and Contingencies:
- Geopolitical Risk: Ongoing military operations in Israel (Israel-Hamas War) pose risks to supply chains, vendor operations, and international flights. While no material adverse effect has been determined as of the filing date, the Company has no specific contingency plans for escalation.
- Litigation: A 2017 financing lawsuit was settled in Q1 2024. A new employment-related demand letter was received in June 2025, which the Company believes is without merit.
- Government Grants: The Company relies on grants from the Israeli Innovation Authority (IIA) and Ministry of Economy, which require royalty payments on future sales.
Key Facts for Investor Verification
- Revenue Status: Verify that the Company has generated zero revenue to date and remains in the pre-commercialization phase despite FDA clearance.
- Dilution Impact: Confirm the extent of share dilution, with outstanding shares tripling from ~19.4M to ~65.8M in nine months due to multiple financing rounds and warrant exercises.
- Cash Burn vs. Runway: Assess the sustainability of the ~$9.3M operating cash burn over nine months against the ~$80M cash position, considering the high cost of commercialization readiness.
- Geopolitical Exposure: Evaluate the specific operational risks associated with the Company's primary R&D and manufacturing base in Israel amidst ongoing regional conflict.
- Inducement Transaction: Review the terms of the September 2025 inducement transaction where investors exchanged lower-strike options for higher-strike options ($4.50) to understand future dilution and capital structure implications.